Cepheid (CPHD) Announces Expanded CDT Gene Presence with Leading C. Difficile Test
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Cepheid Announces Expansion Of The Most Comprehensive Molecular C. Difficile Product Portfolio On The Market
September 15, 2016 4:05 PM EDTSUNNYVALE, Calif., Sept. 15, 2016 /PRNewswire/ -- Particularly perilous Clostridium difficile strains are now potentially easier to detect, thanks to expanded reporting  of binary toxin (CDT) gene presence with the leading molecular test for C. difficile from Cepheid (Nasdaq: CPHD).  Â
The presence of binary toxin-producing C. difficile has been linked to increased disease severity, mortality and disease recurrence.1,2Â Â In addition, strains of C. difficile have been documented that appear to cause disease when they are negative for the well known toxins A and B but positive for... More
